DE122010000020I1
(de)
|
1996-04-25 |
2010-07-08 |
Prosidion Ltd |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
US6258597B1
(en)
*
|
1997-09-29 |
2001-07-10 |
Point Therapeutics, Inc. |
Stimulation of hematopoietic cells in vitro
|
WO1999025719A1
(fr)
*
|
1997-11-18 |
1999-05-27 |
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai |
Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation
|
WO1999038501A2
(fr)
|
1998-02-02 |
1999-08-05 |
Trustees Of Tufts College |
Procede de regulation du metabolisme du glucose et reactifs afferents
|
AU2007202745B2
(en)
*
|
1998-02-02 |
2010-11-18 |
1149336 Ontario, Inc. |
Method of regulating glucose metabolism, and reagents related thereto
|
US6255772B1
(en)
|
1998-02-27 |
2001-07-03 |
Micron Technology, Inc. |
Large-area FED apparatus and method for making same
|
DE19823831A1
(de)
*
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828114A1
(de)
*
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
DE19834591A1
(de)
*
|
1998-07-31 |
2000-02-03 |
Probiodrug Ges Fuer Arzneim |
Verfahren zur Steigerung des Blutglukosespiegels in Säugern
|
US6979697B1
(en)
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
DK1171465T3
(da)
|
1999-03-29 |
2004-12-13 |
Uutech Ltd |
Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
DE19926233C1
(de)
|
1999-06-10 |
2000-10-19 |
Probiodrug Ges Fuer Arzneim |
Verfahren zur Herstellung von Thiazolidin
|
DE19940130A1
(de)
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
JP2003535034A
(ja)
*
|
1999-11-12 |
2003-11-25 |
ギルフォード ファーマシューティカルズ インコーポレイテッド |
ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法
|
GB9928330D0
(en)
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
JP2003518496A
(ja)
*
|
1999-12-23 |
2003-06-10 |
ノバルティス アクチエンゲゼルシャフト |
グルコース代謝障害を処置するための血糖降下薬の使用
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
PT1741447E
(pt)
|
2000-01-21 |
2013-12-11 |
Novartis Ag |
Combinações que compreendem o inibidor da dipeptidilpeptidase-iv
|
AU2001228309A1
(en)
*
|
2000-01-24 |
2001-08-07 |
Novo-Nordisk A/S |
N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
|
JP2003523396A
(ja)
*
|
2000-02-25 |
2003-08-05 |
ノボ ノルディスク アクティーゼルスカブ |
ベータ細胞変性の抑制
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6500804B2
(en)
*
|
2000-03-31 |
2002-12-31 |
Probiodrug Ag |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
EP1891948A1
(fr)
|
2000-10-27 |
2008-02-27 |
Probiodrug AG |
Traitment de troubles neurologiques et neuropsychologiques
|
US7132104B1
(en)
|
2000-10-27 |
2006-11-07 |
Probiodrug Ag |
Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
|
IL155116A0
(en)
*
|
2000-10-27 |
2003-10-31 |
Probiodrug Ag |
Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes
|
DE60139087D1
(de)
*
|
2000-12-14 |
2009-08-06 |
Ortho Mcneil Janssen Pharm |
Verfahren zu Herstellung von Zubereitungen enthaltend einen Steroidhormon und ein Stabilisierungsmittel in nicht-kristallinen Form
|
JPWO2002051836A1
(ja)
*
|
2000-12-27 |
2004-04-22 |
協和醗酵工業株式会社 |
ジペプチジルペプチダーゼ−iv阻害剤
|
DE10100053A1
(de)
*
|
2001-01-02 |
2002-08-22 |
Keyneurotek Ag I G |
Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen
|
KR100883277B1
(ko)
*
|
2001-02-24 |
2009-02-12 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
크산틴 유도체 및 이의 제조방법
|
US7026316B2
(en)
|
2001-03-27 |
2006-04-11 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US6890905B2
(en)
|
2001-04-02 |
2005-05-10 |
Prosidion Limited |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
US20030060494A1
(en)
*
|
2001-05-18 |
2003-03-27 |
Nobuyuki Yasuda |
Pharmaceutical use of N-carbamoylazole derivatives
|
FR2826003B1
(fr)
*
|
2001-06-18 |
2003-08-15 |
Servier Lab |
Nouveaux derives cycliques d'alpha-amino-gamma-hydroxy- amides, leur procede de preparation et les compositions pharmaceutiques que les contiennent
|
EP1406872B1
(fr)
|
2001-06-20 |
2007-12-19 |
Merck & Co., Inc. |
Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete
|
US7253172B2
(en)
|
2001-06-20 |
2007-08-07 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
DE10150203A1
(de)
|
2001-10-12 |
2003-04-17 |
Probiodrug Ag |
Peptidylketone als Inhibitoren der DPIV
|
ATE374181T1
(de)
|
2001-06-27 |
2007-10-15 |
Smithkline Beecham Corp |
Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
EP1492525A2
(fr)
*
|
2001-08-16 |
2005-01-05 |
Probiodrug AG |
Utilisation d'inhibiteurs de la proline endopeptidase pour moduler la concentration d'inositol (1,4,5) triphosphate dependante des cascades de signaux intracellulaires
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
AU2002360453C1
(en)
|
2001-11-26 |
2009-06-18 |
The Brigham And Women's Hospital, Inc. |
Methods for treating autoimmune disorders, and reagents related thereto
|
KR20040058324A
(ko)
*
|
2001-11-26 |
2004-07-03 |
다이이찌 산토리 파마 가부시키가이샤 |
경비흡수용 의약 조성물
|
EP2316470A3
(fr)
|
2001-11-26 |
2011-08-24 |
Trustees Of Tufts College |
Inhibiteurs peptidomimétiques d'enzymes de clivage post-proline
|
AU2003206833B2
(en)
|
2002-02-13 |
2006-07-20 |
F. Hoffmann-La Roche Ag |
Novel pyridin- and pyrimidin-derivatives
|
WO2003068748A1
(fr)
|
2002-02-13 |
2003-08-21 |
F. Hoffmann-La Roche Ag |
Nouveaux derives de pyridine et de quinoline
|
DE60304911D1
(de)
*
|
2002-02-25 |
2006-06-08 |
Eisai Co Ltd |
Xanthin-Derivate als DPP-IV-Inhibitoren
|
PL372316A1
(en)
|
2002-02-28 |
2005-07-11 |
Prosidion Limited |
Glutaminyl based dpiv inhibitors
|
GB0205693D0
(en)
*
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
DE10211555A1
(de)
*
|
2002-03-15 |
2003-10-02 |
Imtm Inst Fuer Medizintechnolo |
Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit sebozytärer Hyperproliferation und veränderten Differenzierungszuständen
|
EP1490335B1
(fr)
*
|
2002-03-25 |
2007-09-19 |
Merck & Co., Inc. |
Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
RU2362555C2
(ru)
*
|
2002-06-03 |
2009-07-27 |
Новартис Аг |
Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
ATE451369T1
(de)
*
|
2002-07-15 |
2009-12-15 |
Merck & Co Inc |
Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7495005B2
(en)
*
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
DE60331747D1
(de)
*
|
2002-09-18 |
2010-04-29 |
Prosidion Ltd |
Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
|
US20040058876A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Torsten Hoffmann |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
|
US7262207B2
(en)
|
2002-09-19 |
2007-08-28 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
JP4491346B2
(ja)
*
|
2002-10-07 |
2010-06-30 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗糖尿病ベータアミノ複素環ジペプチジルペプチダーゼ阻害剤
|
AU2003298596B2
(en)
*
|
2002-10-18 |
2008-12-18 |
Merck Sharp & Dohme Corp. |
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
KR20050072481A
(ko)
|
2002-11-07 |
2005-07-11 |
머크 앤드 캄파니 인코포레이티드 |
당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제억제제로서의 페닐알라닌 유도체
|
US7482337B2
(en)
*
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10254304A1
(de)
*
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
JP2006510630A
(ja)
*
|
2002-12-04 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
|
AU2003297219A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
WO2004065380A1
(fr)
|
2003-01-14 |
2004-08-05 |
Arena Pharmaceuticals Inc. |
Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
|
AU2004206812A1
(en)
|
2003-01-17 |
2004-08-05 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
JP2006516573A
(ja)
|
2003-01-31 |
2006-07-06 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体
|
WO2004067509A1
(fr)
*
|
2003-01-31 |
2004-08-12 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Composé inhibant la dipeptidyl peptidase iv
|
US20040242566A1
(en)
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
JP4806628B2
(ja)
|
2003-05-05 |
2011-11-02 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤
|
KR20110059664A
(ko)
|
2003-05-05 |
2011-06-02 |
프로비오드룩 아게 |
글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
|
MXPA05011861A
(es)
|
2003-05-05 |
2006-02-17 |
Probiodrug Ag |
Uso de efectores de ciclasas de glutamato y glutaminil.
|
EP1625122A1
(fr)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Inhibiteurs de dipeptidyl peptidase
|
JP2006528693A
(ja)
|
2003-05-14 |
2006-12-21 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としての3−アミノ−4−フェニルブタン酸誘導体
|
ATE463492T1
(de)
|
2003-06-06 |
2010-04-15 |
Merck Sharp & Dohme |
Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes
|
US7456204B2
(en)
|
2003-06-17 |
2008-11-25 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7566707B2
(en)
*
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
ATE437876T1
(de)
|
2003-06-20 |
2009-08-15 |
Hoffmann La Roche |
Hexahydropyridoisochinoline als dpp-iv- inhibitoren
|
DE602004030244D1
(de)
|
2003-06-20 |
2011-01-05 |
Hoffmann La Roche |
Itoren
|
EP2085406A1
(fr)
*
|
2003-07-25 |
2009-08-05 |
ConjuChem Biotechnologies Inc. |
Dérivés d'insuline de longue durée et procédés correspondants
|
AU2004261186A1
(en)
|
2003-07-31 |
2005-02-10 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7579357B2
(en)
|
2003-08-13 |
2009-08-25 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005026148A1
(fr)
|
2003-09-08 |
2005-03-24 |
Takeda San Diego, Inc. |
Inhibiteurs de la dipeptidylpeptidase
|
KR101121882B1
(ko)
|
2003-10-15 |
2012-04-12 |
프로비오드룩 아게 |
글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도
|
AU2004285535A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Alza Corporation |
Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
|
US20050171112A1
(en)
*
|
2003-11-03 |
2005-08-04 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
US20100099721A1
(en)
*
|
2003-11-03 |
2010-04-22 |
Probiodrug Ag |
Novel compounds for the treatment of neurological disorders
|
JP2007509898A
(ja)
|
2003-11-03 |
2007-04-19 |
プロビオドルグ エージー |
神経障害治療に有用な組合せ
|
AU2004286857A1
(en)
*
|
2003-11-04 |
2005-05-19 |
Merck & Co., Inc. |
Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7576121B2
(en)
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
ES2524916T3
(es)
|
2003-11-12 |
2014-12-15 |
Sino-Med International Alliance, Inc. |
Compuestos heterocíclicos de ácido borónico
|
US7767828B2
(en)
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR20180050427A
(ko)
|
2003-11-17 |
2018-05-14 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
DE10355304A1
(de)
*
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
ES2940341T3
(es)
|
2004-01-20 |
2023-05-05 |
Novartis Ag |
Formulación y proceso de compresión directa
|
US7230002B2
(en)
|
2004-02-03 |
2007-06-12 |
Glenmark Pharmaceuticals Ltd. |
Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
|
EP1713780B1
(fr)
|
2004-02-05 |
2012-01-18 |
Probiodrug AG |
Nouveaux inhibiteurs de la glutaminyl-cyclase
|
PL1712547T3
(pl)
*
|
2004-02-05 |
2012-04-30 |
Kyorin Seiyaku Kk |
Pochodna bicykloestrowa
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004009039A1
(de)
*
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
EP1593671A1
(fr)
*
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
Inhibiteurs de la DPP-IV
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7393847B2
(en)
*
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
BRPI0418639B8
(pt)
|
2004-03-15 |
2021-05-25 |
Takeda Pharmaceutical |
compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
|
US7179809B2
(en)
*
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
WO2005108382A1
(fr)
|
2004-05-04 |
2005-11-17 |
Merck & Co., Inc. |
Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes
|
US7439370B2
(en)
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
CA2564884A1
(fr)
|
2004-05-18 |
2005-12-08 |
Merck & Co., Inc. |
Derives de la cyclohexylalanine utilises comme inhibiteurs de la dipeptidyl peptidase-iv pour le traitement ou la prevention des diabetes
|
EP1598341A1
(fr)
*
|
2004-05-21 |
2005-11-23 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Inhibiteurs de DPP-IV
|
US7687638B2
(en)
|
2004-06-04 |
2010-03-30 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
EP1604980A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Inhibiteurs de DPP-IV
|
EP1604989A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Inhibiteurs de DPP-IV
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
WO2006019965A2
(fr)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Inhibiteurs de la dipeptidyl peptidase
|
JP2008507541A
(ja)
*
|
2004-07-23 |
2008-03-13 |
ロイヤルティ,スーザン・マリー |
ペプチダーゼ阻害剤
|
EP1623983A1
(fr)
*
|
2004-08-05 |
2006-02-08 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Composés hétérocycliques utilisables comme inhibiteurs de DPP-IV
|
DE102004043944A1
(de)
*
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
*
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
AP2007003973A0
(en)
|
2004-10-12 |
2007-07-30 |
Glenmark Pharmaceuticals Sa |
Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
KR100917545B1
(ko)
*
|
2004-11-30 |
2009-09-16 |
에프. 호프만-라 로슈 아게 |
당뇨병 치료를 위한 dpp-ⅳ 억제제로서의 치환된벤조퀴놀리진
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
AU2005318597A1
(en)
*
|
2004-12-20 |
2006-06-29 |
F. Hoffmann-La Roche Ag |
4-aminopiperidine derivatives
|
EP1828192B1
(fr)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de dipeptidyle peptidase
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
MX2007009760A
(es)
|
2005-02-11 |
2007-11-07 |
Amylin Pharmaceuticals Inc |
Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables.
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
CN101119991B
(zh)
|
2005-02-18 |
2012-01-25 |
田边三菱制药株式会社 |
脯氨酸衍生物的盐,其溶剂合物,及其生产方法
|
MX2007011453A
(es)
|
2005-04-22 |
2008-02-12 |
Alantos Pharmaceuticals Holding Inc |
Inhibidores de la dipeptidil peptidasa-iv.
|
WO2006118127A1
(fr)
*
|
2005-04-26 |
2006-11-09 |
Mitsubishi Tanabe Pharma Corporation |
Agent prophylactique/therapeutique concernant des anomalies du metabolisme sucre/lipide
|
US7521557B2
(en)
*
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
AU2006255097B2
(en)
|
2005-06-06 |
2012-02-09 |
Georgetown University |
Compositions and methods for lipo modeling
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
CA2622069A1
(fr)
*
|
2005-09-08 |
2007-03-15 |
Uutech Limited |
Traitement de l'obesite associee aux diabetes
|
EP1937716A2
(fr)
*
|
2005-09-08 |
2008-07-02 |
Uutech Limited |
Analogues de polypeptide inhibiteur gastrique comme traitement de la fonction reduite des cellules beta pancreatiques du fait du vieillissement
|
CN101374523B
(zh)
|
2005-09-14 |
2012-04-11 |
武田药品工业株式会社 |
用于治疗糖尿病的二肽基肽酶抑制剂
|
JP5122462B2
(ja)
|
2005-09-16 |
2013-01-16 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
EP1971614A1
(fr)
*
|
2005-11-14 |
2008-09-24 |
Probiodrug AG |
Derives de pyrrolidine a fusion de cyclopropyle, en tant qu'inhibiteurs de dipeptidyle peptidase iv (dp iv)
|
DE102005054994B4
(de)
*
|
2005-11-18 |
2015-02-12 |
Bader Gmbh & Co. Kg |
Verkleidungsanordnung, insbesondere Maschinenverkleidung, mit einer Schiebetür und Führungsanordnung hierfür
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
US7915427B2
(en)
*
|
2006-03-08 |
2011-03-29 |
Kyorin Pharmaceuticals Co., Ltd. |
Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof
|
WO2007112347A1
(fr)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
DK1971862T3
(da)
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EA200802054A1
(ru)
|
2006-04-12 |
2009-04-28 |
Пробиодруг Аг |
Ингибиторы фермента
|
CN101437823B
(zh)
|
2006-05-04 |
2014-12-10 |
勃林格殷格翰国际有限公司 |
多晶型
|
EP1852108A1
(fr)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
PE20110235A1
(es)
*
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
US8071583B2
(en)
*
|
2006-08-08 |
2011-12-06 |
Boehringer Ingelheim International Gmbh |
Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
SI2073810T1
(sl)
*
|
2006-09-13 |
2011-12-30 |
Takeda Pharmaceutical |
Uporaba 2-6(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin -1-ilmetil-4-fluoro-benzonitrila za zdravljenje diabetesa, raka, avtoimunskih motenj in infekcije s HIV
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
JP5379692B2
(ja)
|
2006-11-09 |
2013-12-25 |
プロビオドルグ エージー |
潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
|
US8217025B2
(en)
*
|
2006-11-17 |
2012-07-10 |
Harbor Therapeutics, Inc. |
Drug screening and treatment methods
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US9126987B2
(en)
|
2006-11-30 |
2015-09-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
US8143427B2
(en)
*
|
2007-03-22 |
2012-03-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative
|
WO2008120813A1
(fr)
|
2007-04-03 |
2008-10-09 |
Mitsubishi Tanabe Pharma Corporation |
Utilisation combinée de composé inhibiteur de dipeptidylpeptidase iv, et d'adoucisseur
|
DK2142514T3
(da)
|
2007-04-18 |
2015-03-23 |
Probiodrug Ag |
Thioureaderivater som glutaminylcyclase-inhibitorer
|
US7820666B2
(en)
|
2007-05-08 |
2010-10-26 |
Concert Pharmaceuticals, Inc. |
Tetrahydrotriazolopyrazine derivatives and uses thereof
|
EP2025674A1
(fr)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
CN101784278A
(zh)
*
|
2007-08-17 |
2010-07-21 |
贝林格尔.英格海姆国际有限公司 |
用于治疗fab-相关的疾病的嘌呤衍生物
|
US20090076013A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched sitagliptin
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2108960A1
(fr)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
PL2586782T5
(pl)
|
2008-07-03 |
2018-05-30 |
Ratiopharm Gmbh |
Krystaliczne sole sitagliptyny
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
WO2010016584A1
(fr)
*
|
2008-08-07 |
2010-02-11 |
杏林製薬株式会社 |
Procédé de fabrication d'un dérivé de bicyclo[2.2.2]octylamine
|
EP2327406A4
(fr)
*
|
2008-08-14 |
2014-04-09 |
Kyorin Seiyaku Kk |
Composition pharmaceutique stabilisée
|
JP5906086B2
(ja)
*
|
2008-08-15 |
2016-04-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Fab関連疾患の治療に用いるためのプリン誘導体
|
KR20110067096A
(ko)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 및 관련 상태를 치료하기 위한 병용 요법
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
JP2012509892A
(ja)
|
2008-11-26 |
2012-04-26 |
サティオゲン ファーマシューティカルズ,インク. |
サティオゲン類を含有する組成物及び使用の方法
|
WO2010062861A2
(fr)
*
|
2008-11-26 |
2010-06-03 |
Satiogen Pharmaceuticals, Inc. |
Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète
|
KR20110103968A
(ko)
|
2008-12-23 |
2011-09-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
유기 화합물의 염 형태
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
US8404727B2
(en)
|
2009-01-07 |
2013-03-26 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
|
LT2395983T
(lt)
|
2009-02-13 |
2020-07-10 |
Boehringer Ingelheim International Gmbh |
Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
|
EA201101621A1
(ru)
|
2009-05-15 |
2012-05-30 |
Новартис Аг |
Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
|
CN104892502B
(zh)
|
2009-05-15 |
2017-08-04 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的芳基吡啶
|
DK2435409T3
(da)
|
2009-05-28 |
2014-10-27 |
Novartis Ag |
Substituerede aminopropionsyrederivater som neprilysininhibitorer
|
SG176010A1
(en)
|
2009-05-28 |
2011-12-29 |
Novartis Ag |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
WO2011028455A1
(fr)
|
2009-09-02 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Aminotétrahydropanes utilisés comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prévenir le diabète
|
JP5934645B2
(ja)
|
2009-09-11 |
2016-06-15 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
|
CN102666533A
(zh)
|
2009-09-15 |
2012-09-12 |
天蓝制药公司 |
癌症治疗
|
EP2501678B1
(fr)
|
2009-11-17 |
2015-09-23 |
Novartis AG |
Dérivés de l'arylpyridine comme inhibiteurs de l'aldosterone synthase.
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
JP6220126B2
(ja)
|
2009-11-23 |
2017-10-25 |
セルリアン・ファーマ・インコーポレイテッド |
治療的送達のためのシクロデキストリンに基づく重合体
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
WO2011064376A1
(fr)
|
2009-11-30 |
2011-06-03 |
Novartis Ag |
Dérivés d'imidazole en tant qu'inhibiteurs de l'aldostérone synthase
|
WO2011090940A1
(fr)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Polymères à base de cyclodextrine pour administration thérapeutique
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
CN102791704B
(zh)
|
2010-03-10 |
2015-11-25 |
前体生物药物股份公司 |
谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
|
BR112012025592A2
(pt)
|
2010-04-06 |
2019-09-24 |
Arena Pharm Inc |
moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
|
EP2560953B1
(fr)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibiteurs de glutaminyl cyclase
|
BR112012028136A2
(pt)
|
2010-05-05 |
2016-08-09 |
Boehringer Ingelheim Int |
terapia de combinaçao
|
EP2571876B1
(fr)
|
2010-05-21 |
2016-09-07 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
WO2011157827A1
(fr)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
KR20130093012A
(ko)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
PE20131371A1
(es)
|
2010-09-22 |
2013-11-25 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
|
WO2012049566A1
(fr)
|
2010-10-14 |
2012-04-19 |
Japan Tobacco Inc. |
Polythérapie pour l'utilisation dans le traitement du diabète
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
JP6050264B2
(ja)
|
2011-03-16 |
2016-12-21 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
|
WO2012135570A1
(fr)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
|
WO2012145361A1
(fr)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012145603A1
(fr)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012145604A1
(fr)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012170702A1
(fr)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
|
US9051329B2
(en)
|
2011-07-05 |
2015-06-09 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
|
EP2731947B1
(fr)
|
2011-07-15 |
2019-01-16 |
Boehringer Ingelheim International GmbH |
Quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement de la diabète type i et type ii
|
WO2013045413A1
(fr)
|
2011-09-27 |
2013-04-04 |
Sanofi |
Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
|
WO2013055910A1
(fr)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés
|
US20140243281A1
(en)
|
2011-10-28 |
2014-08-28 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
EP2814485A4
(fr)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
Inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prévention du diabète
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
EP2874622A4
(fr)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
WO2014064215A1
(fr)
|
2012-10-24 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibiteurs de la kinase tpl2 pour prévenir ou traiter le diabète et favoriser la survie de cellules β
|
WO2014074668A1
(fr)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
JP6295277B2
(ja)
|
2013-02-14 |
2018-03-14 |
ノバルティス アーゲー |
Nep(中性エンドペプチダーゼ)阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
|
SG11201600211XA
(en)
|
2013-07-25 |
2016-02-26 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure
|
BR112016001376A2
(pt)
|
2013-07-25 |
2017-10-24 |
Novartis Ag |
bioconjugados de polipeptídeos de apelin sintéticos
|
WO2015101916A1
(fr)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Procédé pour la préparation d'empagliflozin
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
DE102014018663A1
(de)
|
2014-12-13 |
2015-03-05 |
Heinz Kiefer |
Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren
|
KR20230151072A
(ko)
|
2015-01-06 |
2023-10-31 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체와 관련된 상태의 치료 방법
|
EA201791668A1
(ru)
|
2015-01-23 |
2017-11-30 |
Новартис Аг |
Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
|
WO2016144862A1
(fr)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
CA3002551A1
(fr)
|
2015-06-22 |
2016-12-29 |
Arena Pharmaceuticals, Inc. |
Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1
|
MX2018007681A
(es)
|
2015-12-28 |
2018-11-14 |
Wockhardt Ltd |
Composicion farmaceutica osmotica oral de vildagliptin.
|
US11013738B2
(en)
*
|
2016-04-29 |
2021-05-25 |
Fundació Hospital Universitari Vall D'hebron—Institut De Recerca |
Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
|
US10155000B2
(en)
|
2016-06-10 |
2018-12-18 |
Boehringer Ingelheim International Gmbh |
Medical use of pharmaceutical combination or composition
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
WO2018162722A1
(fr)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
|
EP3606527A1
(fr)
|
2017-04-03 |
2020-02-12 |
Coherus Biosciences, Inc. |
Agoniste de ppar-gamma pour le traitement de la paralysie supranucléaire progressive
|
EP3424927B1
(fr)
|
2017-07-04 |
2019-04-17 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Procédé efficace de préparation de la sitagliptine au moyen d'une très efficace préparation d'acide 2,4,5-trifluorophenylacétique intermédiaire
|
EP4360651A2
(fr)
|
2017-08-24 |
2024-05-01 |
Novo Nordisk A/S |
Compositions glp-1 et leurs utilisations
|
DK3461819T3
(da)
|
2017-09-29 |
2020-08-10 |
Probiodrug Ag |
Inhibitorer af glutaminylcyklase
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
EP3524605B1
(fr)
|
2018-02-13 |
2019-11-27 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Nouveau procédé efficace pour la préparation de sitagliptine
|
CN113166101A
(zh)
|
2018-11-27 |
2021-07-23 |
诺华股份有限公司 |
作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状五聚体化合物
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
EP3887388A1
(fr)
|
2018-11-27 |
2021-10-06 |
Novartis AG |
Peptides cycliques servant d'inhibiteurs de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) pour le traitement de troubles métaboliques
|
WO2021053076A1
(fr)
|
2019-09-17 |
2021-03-25 |
Novartis Ag |
Multithérapie comprenant de la vildagliptine et de la metformine
|
EP4106724A1
(fr)
|
2020-02-18 |
2022-12-28 |
Novo Nordisk A/S |
Compositions de glp-1 et leurs utilisations
|
WO2022029220A1
(fr)
|
2020-08-05 |
2022-02-10 |
Ellipses Pharma Ltd |
Traitement du cancer à l'aide d'un conjugué polymère contenant de la cyclodextrine-inhibiteur de la topoisomérase et d'un inhibiteur de parp
|
WO2023084449A1
(fr)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Dérivés diaminocyclopentylpyridines pour le traitement d'une maladie ou d'un trouble
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|